Pulmonary vein isolation by means of a novel cryoballoon technology in paroxysmal atrial fibrillation patients: 1‐year outcome from a large Italian multicenter clinical registry
Open Access
- 17 October 2023
- journal article
- research article
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (11) , 1302-1309
Abstract
Introduction: Recently, a new cryoballoon (CB) technology (POLARx; Boston Scientific) has come onto the market. Preliminary data have shown that its acute safety and efficacy are similar to those of the first‐generation CB. The aim of this study was to assess the medium‐term outcome of pulmonary vein isolation (PVI) with the POLARxTM CB in a large multicenter registry.Methods: We prospectively collected data on 125 consecutive patients with paroxysmal atrial fibrillation (AF) who underwent PVI by means of a novel CB system. Two cases of transient phrenic nerve palsy occurred, with full recovery in the 48h post procedure; no major procedure‐related adverse events were reported. During the 90‐day blanking period, 4 (3.2%) patients experienced an early recurrence. After the blanking period, over a mean follow‐up of 411 ± 62 days, 19 patients (15.2%) suffered an AF/atrial tachycardia (AT) recurrence. The 1‐year freedom from AF/AT recurrence was 86.4% (n = 17): 10 (8%) patients had an AF recurrence, 6 (4.8%) had an AT occurrence and 1 (0.8%) suffered both events. Patients with AF/AT recurrences had both a shorter deflation time and total deflation time. Moreover, CB ablations with measured TTI < 90 s and TTI < 60 s were more frequent in patients without AF/AT recurrence (88.5% and 77.4%, respectively) than in those who experienced at least one AF/AT recurrence (67.5% and 55.0%, p = .001 and p = .005, respectively).Conclusion: The novel POLARx cryo‐balloon system is safe and effective for PV isolation, displaying a 1‐year freedom from atrial arrhythmia recurrence of 86.4%, which is in line to that reported with AFA‐Pro CB or RF ablation.Clinical trial registration: Catheter Ablation of Arrhythmias with a High‐Density Mapping System in Real‐World Practice (CHARISMA). URL: http://clinicaltrials.gov/ Identifier: NCT03793998. Registration date: January 4, 2019.Keywords
This publication has 22 references indexed in Scilit:
- Predictive role of early recurrence of atrial fibrillation after cryoballoon ablationEP Europace, 2020
- Standardized pulmonary vein isolation workflow to enclose veins with contiguous lesions: the multicentre VISTAX trialEP Europace, 2020
- Reproducibility of pulmonary vein isolation guided by the ablation index: 1‐year outcome of the AIR registryJournal of Cardiovascular Electrophysiology, 2020
- Reasons for successful clinical outcome following pulmonary vein isolation despite lack of persistent LA‐PV conduction blockPacing and Clinical Electrophysiology, 2019
- Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial FibrillationNew England Journal of Medicine, 2016
- Procedural and biophysical indicators of durable pulmonary vein isolation during cryoballoon ablation of atrial fibrillationHeart Rhythm, 2016
- Predictive Value of Early Atrial Tachyarrhythmias Recurrence After Circumferential Anatomical Pulmonary Vein AblationPacing and Clinical Electrophysiology, 2005
- Delayed cure despite early recurrence after pulmonary vein isolation for atrial fibrillationThe American Journal of Cardiology, 2003
- Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolationJACC, 2002
- Freezing of living cells: mechanisms and implicationsAmerican Journal of Physiology-Cell Physiology, 1984